Tumor mutation burden (TMB), neoantigen load, programmed cell death ligand 1 (PD-L1) levels, impaired DNA mismatch repair (MMR), and microsatellite instability (MSI) have been found to affect response of cancer cells to immunotherapy [8, 9]. Here, CD274 is linked to neoplasm.